Market Update (NASDAQ:ESRX): Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

[Reuters] – The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc’s newly approved hepatitis C treatment and, in most cases, will no longer . . . → Read More: Market Update (NASDAQ:ESRX): Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival Similar Articles: Stock Update (NASDAQ:ESRX): Express Scripts Announces 3rd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point Market Update (NASDAQ:ESRX): Express Scripts Holding Company Announces Third Quarter 2014 Earnings Conference Call Company Update: Express Scripts Holding Company (NASDAQ:ESRX) – New Express Scripts Analysis Reveals Trends Among Health Exchange Members